SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
Nature Medicine2016Vol. 23(2), pp. 250–255
Citations Over TimeTop 10% of 2016 papers
Constanze Schneider, Thomas Oellerich, Hanna‐Mari Baldauf, Sarah-Marie Schwarz, Dominique Thomas, Robert Flick, Hanibal Bohnenberger, Lars Kaderali, Lena Stegmann, Anjali Cremer, Margarethe Martin, Julian J.K. Lohmeyer, Martin Michaelis, Veit Hornung, Christoph Schliemann, Wolfgang E. Berdel, Wolfgang Hartmann, Eva Wardelmann, Federico Comoglio, Martin‐Leo Hansmann, Alexander F. Yakunin, Gerd Geißlinger, Philipp Ströbel, Nerea Ferreirós, Hubert Serve, Oliver T. Keppler, Jindřich Činátl
Related Papers
- → Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines(2015)18 cited
- → Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia(2023)5 cited
- → [Advances in the mouse models of myeloid leukemia].(2019)1 cited
- → HSA-MIR-12462 INHIBITS THE PROLIFERATION AND RESTORES THE SUSCEPTIBILITY TO CYTARABINE OF ACUTE MYELOID LEUKEMIA (AML) THROUGH INHIBITION OF GLI1(2019)
- Analyses of therapeutic effects using rludarabine and cytarabine on acute myeloid leukemia at different stages during treatment(2009)